Agilent Technologies Inc. announced an agreement with Incyte that will bring together Agilent?s expertise and proven track record in the development of companion diagnostics (CDx) to support the development and commercialization of Incyte?s hematology and oncology portfolio. The value of the companion diagnostics market is predicted to expand to nearly USD 14B by 2030,1 driven in part by the power of these tests to inform treatment decisions for a growing range of cancers and other chronic diseases. Developed for use with targeted therapeutics, companion diagnostics are used to evaluate expression of biomarkers and identify patients that are likely to benefit from treatment with the targeted therapeutic products.

The agreement between Agilent and Incyte allows the companies to collaborate on CDx development programs. This will enable Agilent to continue to expand its companion diagnostics portfolio with novel biomarkers and Incyte to leverage Agilent?s expertise in IVD assay development, global regulatory approvals, and commercialization to support clinical trials as well as the potential registration and commercialization of CDx in the United States and Europe. With an established and growing portfolio of world-class chemistries and technologies, Agilent has a strong track record as a provider and partner for companion diagnostics development across the precision oncology sector. This year, Agilent celebrates the 25th anniversary of HercepTest, a critical tool for assessing HER2 expression in breast cancers.

Since the launch of HercepTest, Agilent has introduced several additional CDx tests. Among these, the PDL-1 IHC 22C3 franchise has been particularly successful, offering a continually expanding range of tests for assessing PDL-1 expression.